Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies

The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of pharmacology Ročník 978; s. 176803
Hlavní autoři:	Naeimzadeh, Yasaman, Tajbakhsh, Amir, Nemati, Mahnaz, Fallahi, Jafar
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 05.09.2024
Témata:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast neoplasms Breast Neoplasms - drug therapy Clinical Trials as Topic Diabetes mellitus Female Gene mutations Humans Precision medicine SGLT2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Breast neoplasms Gene mutations Precision medicine Antineoplastic agents SGLT2 inhibitor Diabetes mellitus
ISSN:	0014-2999, 1879-0712, 1879-0712
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!